中国创新药企,找到新的印钞机

健识局
Oct 03, 2025

10月2日,宜明昂科的双抗药物PD-L1/VEGF药物IMM2510用于非小细胞肺癌的耐药治疗申报国内3期临床。10月3日,宜明昂科股价当即拉升9%。在所有PD-L1/VEGF双抗中,宜明昂科的品种算是比较受关注的。3月以来,宜明昂科股价涨跌幅达到180%,现在较最低点股价更是已经翻了近3倍。2024年,依沃西单抗与K药的对垒点燃了PD-(L)1/VEGF双抗的热度。此后这一赛道吸引了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10